These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 20089004)

  • 1. Towards (cost)effective cardiovascular risk management: using new drugs vs. the better use of available ones.
    Shantsila A; Lip GY
    Int J Clin Pract; 2010 Jan; 64(2):138-40. PubMed ID: 20089004
    [No Abstract]   [Full Text] [Related]  

  • 2. Drug treatment and cost of cardiovascular disease in Australia.
    Ademi Z; Liew D; Chew D; Conner G; Shiel L; Nelson M; Soman A; Steg G; Bhatt DL; Reid C;
    Cardiovasc Ther; 2009; 27(3):164-72. PubMed ID: 19689615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ACE inhibitors: back to prime time?
    Gupta M; Verma S; Mancini GB
    Heart; 2007 Sep; 93(9):1015-6. PubMed ID: 17699166
    [No Abstract]   [Full Text] [Related]  

  • 4. [The elderly cardiovascular patient in general practice. Health care costs--drugs--economic feasibility].
    Schmidt K
    Fortschr Med; 1996 Mar; 114(7):43-4. PubMed ID: 8900969
    [No Abstract]   [Full Text] [Related]  

  • 5. The cost-effectiveness of cardiovascular medicine: victims of our own success?
    Vardas PE
    Hellenic J Cardiol; 2013; 54(2):155-6. PubMed ID: 23557621
    [No Abstract]   [Full Text] [Related]  

  • 6. The cost effectiveness of cardiovascular medicines.
    Hay J
    Curr Atheroscler Rep; 2005 Mar; 7(2):79-80. PubMed ID: 15727719
    [No Abstract]   [Full Text] [Related]  

  • 7. Reference-based pricing of prescription drugs.
    McLaughlin PR
    Can J Cardiol; 1997 Jan; 13(1):31-2. PubMed ID: 9039062
    [No Abstract]   [Full Text] [Related]  

  • 8. Past the wall in cardiovascular R&D.
    Topol EJ
    Nat Rev Drug Discov; 2009 Apr; 8(4):259. PubMed ID: 19348004
    [No Abstract]   [Full Text] [Related]  

  • 9. [Cardiovascular pharmacotherapy in old age: How beneficial is it? What does it cost?].
    Gysling E
    Praxis (Bern 1994); 1995 Oct; 84(44):1248-51. PubMed ID: 7491446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Terminology I would like to see disappear.
    Detsky AS
    Am Heart J; 1999 May; 137(5):S51-2. PubMed ID: 10220597
    [No Abstract]   [Full Text] [Related]  

  • 11. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Role of government agencies regarding cost-effectiveness claims: FDA perspective.
    Temple R
    Am Heart J; 1999 May; 137(5):S75-7. PubMed ID: 10220602
    [No Abstract]   [Full Text] [Related]  

  • 12. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. A survey of standards and guidelines for cost-effectiveness analysis in health care.
    Stewart A; Schmier JK; Luce BR
    Am Heart J; 1999 May; 137(5):S53-61. PubMed ID: 10220598
    [No Abstract]   [Full Text] [Related]  

  • 13. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Role of economic models in randomized clinical trials.
    Hlatky MA
    Am Heart J; 1999 May; 137(5):S41-6. PubMed ID: 10220595
    [No Abstract]   [Full Text] [Related]  

  • 14. [Cardiovascular pharmacology in the 90s: where are we?].
    Marín Huerta E; Rayo I
    Rev Esp Cardiol; 1994 Jun; 47(6):390-402. PubMed ID: 8066311
    [No Abstract]   [Full Text] [Related]  

  • 15. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Product labeling and pharmacoeconomic information.
    Morris LA
    Am Heart J; 1999 May; 137(5):S78-80. PubMed ID: 10220603
    [No Abstract]   [Full Text] [Related]  

  • 16. What future does the pharmaceutical industry have in the cardiovascular world?
    Braunwald E
    Eur Heart J; 2013 Apr; 34(13):943-4. PubMed ID: 23546415
    [No Abstract]   [Full Text] [Related]  

  • 17. Predictors of annual pharmaceutical costs in Australia for community-based individuals with, or at risk of, cardiovascular disease: analysis of Australian data from the REACH registry.
    Ademi Z; Liew D; Hollingsworth B; Steg PG; Bhatt DL; Reid CM;
    Am J Cardiovasc Drugs; 2010; 10(2):85-94. PubMed ID: 20334445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screen-and-treat strategies for albuminuria to prevent cardiovascular and renal disease: cost-effectiveness of nationwide and targeted interventions based on analysis of cohort data from the Netherlands.
    Boersma C; Gansevoort RT; Pechlivanoglou P; Visser ST; van Toly FF; de Jong-van den Berg LT; de Jong PE; Postma MJ;
    Clin Ther; 2010 Jun; 32(6):1103-21. PubMed ID: 20637965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Merck Serono targets convenient, affordable medicines for patients at risk.
    Cardiovasc J Afr; 2009; 20(1):77. PubMed ID: 19287822
    [No Abstract]   [Full Text] [Related]  

  • 20. [Rationale for the pharmacologic treatment of cardiovascular diseases].
    Perdigão C
    Rev Port Cardiol; 1998 May; 17(5):453-61. PubMed ID: 9656768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.